LOS ANGELES–(BUSINESS WIRE)–MedMen Enterprises Inc. (“MedMen” or the “Company”) (CSE: MMEN) (OTCQX: MMNFF) today released its consolidated financial results second quarter 2020 ended December 28, 2019. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

Management Commentary

“We feel positive about the progress made while remaining aware there is still substantial work to be done. The business is focused on the execution of a strategy to streamline operations, strengthen its balance sheet and bring in additional capital. The sustained power of the brand and consistent consumer loyalty is a regular reminder of our strengths and the opportunities within reach,” said Ben Rose, executive chairman of the Board and Chief Investment Officer of Wicklow Capital.

“This is a pivotal time for the Company where we have the opportunity to re-assess the business and narrow the focus on what we do best – retail, to continue to cut costs and to execute on four-wall economics with a path to profitability,” said Ryan Lissack, Interim Chief Executive Officer. “I look forward to transitioning the company into its next chapter, which will be defined by financial discipline and strategic growth to drive long-term value creation for the Company and its stakeholders.”

Second Quarter Fiscal 2020 Review

Financials:

• Revenue: Systemwide revenue across MedMen’s operations in California, Nevada, New York, Illinois and Florida increased to $44.1 million for the quarter, up 50% year-over-year and 11% sequentially. Revenue figures do not include the Company’s operations in Arizona, which are in the process of being divested and are classified as discontinued operations in the Company’s financials.
• Retail Gross Margin: Gross margins across retail operations were 51% compared to 52% in the prior quarter. In California, retail gross margin was 52%, compared to 53% in the previous quarter.
• Corporate SG&A: Corporate SG&A totaled $26.8 million, a 30% decrease from fiscal second quarter 2019, representing $46 million in annualized savings since the initial cost-cutting efforts began. The Company revised its corporate SG&A target to an annualized run-rate of $65 million to be achieved by MedMen’s fiscal third quarter 2020.
• Adjusted EBITDA: The Company reported an Adjusted EBITDA loss of $35.1 million for the quarter. The Adjusted EBITDA for the quarter does not include additional headcount reduction and retail optimization efforts the Company executed on subsequent to the quarter end. The Company’s cultivation and manufacturing facilities contributed to $11.4 million of the total EBITDA loss.
• California Retail EBITDA: Across its California retail footprint, the Company recorded a four-wall EBITDA margin before local taxes and distribution expenses of 16%, compared to 17% in the previous quarter.

Retail Highlights:

• California: California retail revenue totaled $32.4 million for the second quarter, representing an 8% sequential increase from the previous quarter, and 37% increase from the same period last year. On a same-store basis, California retail stores are up 16% from the same period last year. The Beverly Hills, Santa Ana, LAX, Abbot Kinney and Downtown Los Angeles locations were up 43%, 43%, 40%, 30% and 30%, respectively, compared to the same period last year.
• Nevada: Nevada retail revenue totaled $5.9 million for the second quarter, representing a 10% sequential increase from the previous quarter, and a 75% increase from same period last year. MedMen Paradise, the Company’s flagship store in Las Vegas, recorded a 10% sequential revenue increase. The store was not open for the full second quarter 2019 for a year-over-year comparison.
• Florida: During the quarter, the Company opened four locations in Florida, which include retail stores in Jacksonville Beach, Orlando-International Drive, Tallahassee and Sarasota. The Company operates a total of eight stores across the state. The Company is currently undergoing a strategic review of its Florida footprint to determine timing of additional store openings.
• Illinois: The Company began operating its second store in Illinois, located in Evanston, on December 3, 2019. Both the new Evanston store and existing Oak Park store are currently serving recreational customers. The Company expects to have a total of four stores in Illinois by end of calendar year 2020.
• Massachusetts: The Company’s Fenway location is pending final regulatory approval and construction is anticipated to begin in calendar year 2020. In Newton, Massachusetts MedMen has signed a lease on a retail location and now is awaiting regulatory approvals.
• New York: The Company operates four medical dispensaries in the state, with a flagship location on Fifth Avenue near Bryant Park.
• Arizona: The Company is currently in the process of divesting its Arizona footprint, which includes three retail locations and various cultivation and manufacturing operations.

Capital Markets and Financing Activities:

• Credit Facility: On November 27, 2019, the Company closed on $10 million of additional funding under Tranche 3 of the existing facility with Gotham Green Partners and its affiliates. As part of the amendments which were executed along with the funding, additional changes were made to the facility to provide greater flexibility to the Company.
• Equity Investment: On December 27, 2019, the Company announced that it signed definitive documentation for its offering of Class B subordinate voting shares for aggregate gross proceeds of $20 million at a price per share of $0.43. Closing of the equity placement occurred in January 2020.

Corporate Governance:

• On December 10, 2019, Co-Founder Andrew Modlin granted Ben Rose, Executive Chairman of the Board, a limited proxy in respect of 815,295 Class A Super Voting shares, which represented 50% of the total Class A Super Voting Shares for a period of one year. Such proxy may not be used to eliminate or change the rights of such shares or otherwise alter or amend the organizational documents of the Company.
• Effective February 1, 2020, Adam Bierman, Co-Founder and Chief Executive Officer stepped down as Chief Executive Officer and agreed to surrender his Class A Super Voting shares. The board of directors named the Company’s Chief Technology Officer, Ryan Lissack, as Interim Chief Executive Officer. Following expiration of the limited proxy granted by Andrew Modlin to Ben Rose, MedMen will only have one class of outstanding shares, Class B subordinate voting shares, each of which entitle the holder to one vote.

Subsequent Events:

• Definitive Agreement on Sale of Non-Core Asset: On February 25, 2020 the Company entered into definitive agreements to assign its rights to acquire a licensed cultivation and manufacturing facility in Hillcrest, Illinois (“Hillcrest Facility”) for total gross proceeds of $17 million (“Hillcrest Transaction”). The Company previously received the right to acquire the Hillcrest Facility as part of its merger termination agreement with PharmaCann, LLC (“PharmaCann”). As part of the Hillcrest Transaction, the Company received an initial payment of $10 million (the “Initial Payment”). The second payment of $7 million is due prior to the closing of the Hillcrest Transaction, expected in the coming weeks.
• MedMen 2020 Annual General Meeting Results: The Annual General Meeting of MedMen shareholders was held on February 21, 2020 in Toronto, Canada under Executive Chairman, Ben Rose. Shareholders adopted all the resolutions submitted for approval. Shareholders re-elected Ben Rose, Adam Bierman and Jay Brown to the Board of Directors and added new members Mel Elias, Cameron Smith, and Chris Ganan. MNP LLP was re-appointed as the auditors of the Company.
• Secured Term Loan Amendment: On January 14, 2020, the Company announced the execution and closing of definitive documentation for amendments to the terms and conditions of the $78 million senior secured term loan with funds managed by Stable Road and its affiliates.

New Independent Board Members:

• Mel Elias: Mr. Mel Elias, an active investor, entrepreneur and developer in Los Angeles has past and present board experience in CPG and consumer retail businesses both in the US and internationally. He was President and CEO of The Coffee Bean & Tea Leaf for 6 years, until it was sold in 2013.
• Cameron Smith: Mr. Cameron Smith currently operates a private angel investment and advisory fund that focuses on health food. Prior to his investment and advisory business, Mr. Smith was General Counsel of The Island ENC, Inc., President of Quantlab Financial and worked at the SEC.

ADDITIONAL INFORMATION

Additional information relating to the Company’s fiscal second quarter 2020 results is available on SEDAR at www.sedar.com in the Company’s Interim Financial Statements and Management Discussion & Analysis (“MD&A”) for the quarter.

MedMen refers to certain non-IFRS financial measures such as Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), adjusted EBITDA (defined as earnings before interest, taxes, depreciation, amortization, less certain non-cash equity compensation expense, including one-time transaction fees and all other non-cash items) and four-wall retail gross margins. These measures do not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other issuers.

Please see the “Supplemental Information (Unaudited) Regarding Non-IFRS Financial Measures” at the end of this press release and the MD&A for more detailed information regarding non-IFRS financial measures.

CONFERENCE CALL AND WEBCAST:

MedMen Enterprises will host a conference call and audio webcast with Executive Chairman, Ben Rose, Interim Chief Executive Officer Ryan Lissack and Chief Financial Officer Zeeshan Hyder today at 5:00 pm Eastern to discuss the financial results in further detail.

Webcast Information:

A live audio webcast of the call will be available on the Events and Presentations section of MedMen’s website at: https://investors.medmen.com/events-and-presentations/default.aspx and will be archived for replay.

Calling Information:

Toll Free Dial-In Number: (844) 559-7829

International Dial-In Number: (647) 689-5387

Conference ID: 8898600

ABOUT MEDMEN:

MedMen is North America’s premium cannabis retailer with flagship locations in Los Angeles, Las Vegas, Chicago and New York. Through a robust selection of high-quality products, including MedMen-owned brands [statemade], LuxLyte and MedMen Red, and a team of cannabis-educated associates, MedMen has defined the next generation discovery platform for cannabis and all its benefits. MedMen’s industry-leading technology enables a fully compliant, owned-and-operated delivery service and MedMen Buds, a nationwide loyalty program. MedMen believes that a world where cannabis is legal and regulated is safer, healthier and happier. Learn more at www.medmen.com

Cautionary Note Regarding Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only MedMen’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of MedMen’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “target of”, “objectives”, “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein may include, but are not limited to, expectations regarding the timing and results of the Company’s focus on retail operations, continued cost cutting efforts, emphasis on four-wall economics, and other considerations that could impact achieving positive EBITDA.

This forward-looking information is based on certain assumptions made by management and other factors used by management in developing such information.

Although MedMen believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and MedMen does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to MedMen or persons acting on its behalf are expressly qualified in its entirety by this notice.

Non-IFRS Measures

This press release uses certain non-IFRS measures. Management uses non-IFRS financial measures, in addition to IFRS financial measures, to understand and compare operating results across accounting periods, for financial and operational decision-making, for planning and forecasting purposes and to evaluate the Company’s financial performance. These measures include EBITDA, which is defined as net income or loss adjusted for net interest and other financing costs, provision for income taxes, and amortization and depreciation.

Management believes that these non-IFRS financial measures assess the Company’s ongoing business in a manner that allows for meaningful comparisons and analysis of trends in the business, as they facilitate comparing financial results across accounting periods and to those of peer companies. Management also believes that these non-IFRS financial measures enable investors to evaluate the Company’s operating results and future prospects in the same manner as management. These non-IFRS financial measures may also exclude expenses and gains that may be unusual in nature, infrequent or not reflective of the Company’s ongoing operating results.

As there are no standardized methods of calculating these non-IFRS financial measures, the Company’s methods may differ from those used by others, and accordingly, the use of these measures may not be directly comparable to similarly titled measures used by others. Accordingly, these non-IFRS financial measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS.

SOURCE: MedMen Enterprises

	MEDMEN ENTERPRISES INC.
	UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
	DECEMBER 28, 2019 AND JUNE 29, 2019
	(Amounts Expressed in United States Dollars Unless Otherwise Stated)
			December 28, 2019			June 29, 2019
	ASSETS
	Current Assets:
	Cash and Cash Equivalents		$ 26,000,362			$ 33,753,751
	Restricted Cash		115,873			55,618
	Accounts Receivable		1,357,363			1,487,430
	Current Portion of Prepaid Rent – Related Party		–			1,580,205
	Prepaid Expenses		6,652,852			14,147,213
	Derivative Assets		282,785			5,213,126
	Income Taxes Receivable		1,527,059			3,459,019
	Biological Assets		2,432,150			3,076,158
	Inventory		34,176,175			29,176,192
	Assets Held for Sale		55,284,834			–
	Other Current Assets		19,694,073			18,913,039
	Due from Related Party		3,640,285			4,921,455
	Total Current Assets		151,163,811			115,783,206
	Non-Current Assets:
	Prepaid Rent – Related Party, Net of Current Portion		–			4,327,077
	Property and Equipment, Net		436,880,106			220,989,461
	Intangible Assets, Net		166,827,359			175,552,837
	Goodwill		61,322,038			85,560,531
	Other Assets		27,818,707			32,417,123
	Total Non-Current Assets		692,848,210			518,847,029
	TOTAL ASSETS		$ 844,012,021			$ 634,630,235
	LIABILITIES AND SHAREHOLDERS’ EQUITY
	LIABILITIES:
	Current Liabilities:
	Accounts Payable and Accrued Liabilities		$ 83,928,235			$ 49,794,041
	Income Taxes Payable		26,563,112			16,873,177
	Other Current Liabilities		20,532,350			10,550,240
	Derivative Liabilities		1,313,781			9,343,485
	Current Portion of Lease Liabilities		15,867,608			2,502,813
	Current Portion of Notes Payable		20,269,053			20,229,641
	Liabilities Held for Sale		15,434,001			–
	Due to Related Party		4,922,974			5,640,817
	Total Current Liabilities		188,831,114			114,934,214
	Non-Current Liabilities:
	Lease Liabilities, Net of Current Portion		293,974,591			95,726,766
	Other Non-Current Liabilities		10,175,936			30,877,794
	Deferred Tax Liabilities		21,284,889			24,578,609
	Senior Secured Convertible Credit Facility		141,438,823			90,270,837
	Notes Payable, Net of Current Portion		70,551,431			77,392,749
	Total Non-Current Liabilities		537,425,670			318,846,755
	TOTAL LIABILITIES		726,256,784			433,780,969
	SHAREHOLDERS’ EQUITY:
	Share Capital		666,194,580			556,651,469
	Contributed Surplus		72,800,302			63,026,656
	Accumulated Deficit		(480,684,893	)		(383,622,726	)
	Total Equity Attributable to Shareholders of MedMen Enterprises Inc.		258,309,989			236,055,399
	Non-Controlling Interest		(140,554,752	)		(35,206,133	)
	TOTAL SHAREHOLDERS’ EQUITY		117,755,237			200,849,266
	TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY		$ 844,012,021			$ 634,630,235

	MEDMEN ENTERPRISES INC.
	UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
	13 AND 26 WEEKS ENDED DECEMBER 28, 2019 AND DECEMBER 29, 2018
	(Amounts Expressed in United States Dollars Unless Otherwise Stated)
			13 Weeks Ended						26 Weeks Ended
			December 28, 2019			December 29, 2018			December 28, 2019			December 29, 2018
	Revenue		$ 44,065,882			$ 29,417,295			$ 83,735,878			$ 50,877,490
	Cost of Goods Sold		39,519,070			16,379,734			56,904,668			26,189,068
	Gross Profit Before Fair Value Adjustments		4,546,812			13,037,561			26,831,210			24,688,422
	Realized Fair Value of Inventory Sold		5,263,968			(244,343	)		(5,477,005	)		(2,196,923	)
	Unrealized Gain on Changes in Fair Value of Biological Assets		2,963,849			2,878,271			8,458,688			2,882,915
	Gross Profit		12,774,629			15,671,489			29,812,893			25,374,414
	Expenses:
	General and Administrative		52,494,758			64,148,223			99,830,424			129,887,674
	Sales and Marketing		3,610,001			8,602,293			9,393,729			13,402,525
	Depreciation and Amortization		13,137,432			3,379,803			23,886,064			5,830,123
	Total Expenses		69,242,191			76,130,319			133,110,217			149,120,322
	Loss from Operations		(56,467,562	)		(60,458,830	)		(103,297,324	)		(123,745,908	)
	Other Expense (Income):
	Interest Expense		12,247,416			2,269,040			23,865,465			4,389,325
	Interest Income		(265,379	)		(284,889	)		(634,721	)		(284,889	)
	Amortization of Debt Discount and Loan Origination Fees		4,283,443			2,001,820			7,215,248			2,350,326
	Change in Fair Value of Derivatives		(388,697	)		(5,389,178	)		(521,592	)		(6,163,107	)
	Unrealized Gain on Changes in Fair Value of Investments		(5,034,160	)		(1,194,000	)		(16,514,481	)		(1,194,000	)
	Unrealized Gain on Changes in Fair Value of Contingent Consideration		(4,630,589	)		–			(1,887,146	)		–
	Other Expense		6,035,378			3,152,422			26,468,035			3,258,049
	Total Other Expense		12,247,412			555,215			37,990,808			2,355,704
	Loss from Continuing Operations Before Provision for Income Taxes		(68,714,974	)		(61,014,045	)		(141,288,132	)		(126,101,612	)
	Provision for Income Taxes		6,060,482			2,186,567			12,081,003			3,595,225
	Net Loss and Comprehensive Loss from Continuing Operations		(74,775,456	)		(63,200,612	)		(153,369,135	)		(129,696,837	)
	Net Loss from Discontinued Operations, Net of Taxes		(21,657,696	)		(1,369,606	)		(25,699,476	)		(1,369,606	)
	Net Loss and Comprehensive Loss		(96,433,152	)		(64,570,218	)		(179,068,611	)		(131,066,443	)
	Net Loss and Comprehensive Loss Attributable to Non-Controlling Interest		(55,824,247	)		(45,885,355	)		(106,983,391	)		(99,903,648	)
	Net Loss and Comprehensive Loss Attributable to Shareholders of MedMen Enterprises Inc.		$ (40,608,905	)		$ (18,684,863	)		$ (72,085,220	)		$ (31,162,795	)
	Loss Per Share – Basic and Diluted:
	From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc.		$ (0.09	)		$ (0.23	)		$ (0.24	)		$ (0.54	)
	From Discontinued Operations		$ (0.10	)		$ (0.02	)		$ (0.13	)		$ (0.02	)
	Weighted-Average Shares Outstanding – Basic and Diluted		220,467,070			74,243,033			196,211,921			54,950,660

MEDMEN ENTERPRISES INC.
UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
26 WEEKS ENDED DECEMBER 28, 2019 AND DECEMBER 29, 2018
(Amounts Expressed in United States Dollars Unless Otherwise Stated)
		26 Weeks Ended
		December 28,			December 29,
		2019			2018
CASH FLOW FROM OPERATING ACTIVITIES:
Net Loss and Comprehensive Loss from Continuing Operations		$ (153,369,135	)		$ (129,696,837	)
Adjustments to Reconcile Net Loss and Comprehensive Loss to Net Cash Used in Continued Operating Activities:
Unrealized Gain on Changes in Fair Value of Biological Assets		(8,458,688	)		(2,882,915	)
Deferred Tax Expense		274,320			–
Interest Expense		23,865,465			–
Realized Fair Value of Inventory Sold		5,263,968			2,196,924
Depreciation and Amortization		27,808,258			6,280,788
Loss on Sale of Property		–			2,626,216
Amortization of Debt Discount and Loan Origination Fees		7,215,248			2,001,820
Change in Fair Value of Contingent Consideration		(1,887,146	)		–
Accretion of Deferred Gain on Sale of Property		(504,168	)		(84,995	)
Unrealized Gain on Changes in Fair Value of Investments		(16,514,481	)		(1,194,000	)
Loss on Extinguishment of Debt		20,852,426			715,979
Share-Based Compensation		9,512,325			22,653,899
Shares Issued for Acquisition Costs		421,497			747,562
Change in Fair Value of Derivatives		(521,592	)		(6,163,107	)
Changes in Operating Assets and Liabilities:
Accounts Receivable		(165,585	)		(152,820	)
Prepaid Rent – Related Party		–			947,500
Prepaid Expenses		7,158,485			(6,483,803	)
Income Taxes Receivable		1,931,510			–
Biological Assets		3,086,506			(34,410	)
Inventory		(9,123,763	)		(5,429,114	)
Other Current Assets		(180,292	)		(7,706,609	)
Due from Related Party		59,516			(5,013,364	)
Other Assets		(7,867,887	)		3,841,116
Accounts Payable and Accrued Liabilities		30,120,908			6,680,725
Income Taxes Payable		11,589,422			–
Other Current Liabilities		732,695			(5,430,608	)
Due to Related Party		(5,792,918	)		(4,060,144	)
NET CASH USED IN CONTINUED OPERATING ACTIVITIES		(54,493,106	)		(125,640,197	)
					–
Net Cash Provided by Discontinued Operating Activities		2,137,324			637,744
NET CASH USED IN OPERATING ACTIVITIES		(52,355,782	)		(125,002,453	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of Property and Equipment		(47,972,430	)		(54,765,288	)
Internally-Developed Software Costs Capitalized		(2,973,983	)		–
Proceeds from Sale of Assets Held for Sale		4,952,822			–
Purchase of Investments		–			(8,304,833	)
Proceeds from Sale of Property		20,400,000			24,073,319
Proceeds from Sale of Investments		12,500,000			–
Acquisition of Businesses, Net of Cash Acquired		(1,000,000	)		(30,686,541	)
Additions to Restricted Cash		(60,255	)		2,998,619
					–
NET CASH USED IN CONTINUED INVESTING ACTIVITIES		(14,153,846	)		(66,684,724	)
					–
Net Cash Used in Discontinued Investing Activities		(1,491,328	)		(496,440	)
NET CASH USED IN INVESTING ACTIVITIES		(15,645,174	)		(67,181,164	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Exercise of Warrants for MedMen Corp Redeemable Shares		–			8,521,268
Issuance of Subordinate Voting Shares for Cash		52,599,252			115,289,679
Cash Received in Advance for Issuance of Equity		2,000,000			–
Proceeds from Issuance of Senior Secured Convertible Credit Facility		35,000,000			–
Proceeds from Issuance of Notes Payable		2,750,000			93,943,539
Principal Repayments of Notes Payable		(13,482,371	)		(24,739,101	)
Lease Liability Payments		(11,824,757	)		(42,775	)
Interest Paid on Notes Payable and Senior Secured Convertible Credit Facility		(4,112,580	)		–
Debt Issuance Costs		(1,197,974	)		(2,019,472	)
(Distributions to) Contributions from Non-Controlling Interest		(310,633	)		290,000
					–
NET CASH PROVIDED BY FINANCING ACTIVITIES		61,420,937			191,243,138
					–
NET DECREASE IN CASH AND CASH EQUIVALENTS		(6,580,019	)		(940,479	)
					–
Cash Included in Assets Held for Sale		(1,173,370	)		–
Cash and Cash Equivalents, Beginning of Period		33,753,751			79,159,970
					–
CASH AND CASH EQUIVALENTS, END OF PERIOD		$ 26,000,362			$ 78,219,491

	MEDMEN ENTERPRISES INC.
	NON-IFRS RECONCILIATION
	26 WEEKS ENDED DECEMBER 28, 2019 AND DECEMBER 29, 2018
	(Amounts Expressed in United States Dollars Unless Otherwise Stated)
			13 Weeks Ended						26 Weeks Ended
			December 28, 2019			December 29, 2019			December 28, 2019			December 29, 2019
	Net Loss from Continuing Operations (IFRS)		$ (74,775,456	)		$ (63,200,612	)		$ (153,369,135	)		$ (129,696,837	)
	Add (Deduct) Impact of:
	Transaction Costs and Other One-Time Costs		17,815,931			4,234,328			18,830,468			5,657,679
	Share-Based Compensation		2,551,641			11,470,363			8,963,050			22,653,901
	Other Non-Cash Operating Costs		(16,400,038	)		(6,064,684	)		(279,537	)		(4,785,050	)
	Total Adjustments		3,967,534			9,640,007			27,513,981			23,526,530
	Adjusted Net Loss from Continuing Operations (Non-IFRS)		$ (70,807,922	)		$ (53,560,605	)		$ (125,855,154	)		$ (106,170,307	)
	Net Loss from Continuing Operations (IFRS)		$ (74,775,456	)		$ (63,200,612	)		$ (153,369,135	)		$ (129,696,837	)
	Add (Deduct) Impact of:
	Net Interest and Other Financing Costs		11,982,038			2,601,785			23,230,745			5,011,817
	Provision for Income Taxes		6,060,482			2,186,567			12,081,003			3,595,225
	Amortization and Depreciation		17,679,214			5,003,023			35,023,510			7,723,731
	Total Adjustments		35,721,734			9,791,375			70,335,258			16,330,773
	EBITDA from Continuing Operations (Non-IFRS)		$ (39,053,722	)		$ (53,409,237	)		$ (83,033,877	)		$ (113,366,064	)
	EBITDA from Continuing Operations (Non-IFRS)		$ (39,053,722	)		$ (53,409,237	)		$ (83,033,877	)		$ (113,366,064	)
	Add (Deduct) Impact of:
	Transaction Costs and Other One-Time Costs		17,815,931			4,234,328			18,830,468			5,657,679
	Share-Based Compensation		2,551,641			11,470,363			8,963,050			22,653,901
	Other Non-Cash Operating Costs		(16,400,038	)		(6,064,684	)		(279,537	)		(4,785,050	)
	Total Adjustments		3,967,534			9,640,007			27,513,981			23,526,530
	Adjusted EBITDA from Continuing Operations (Non-IFRS)		$ (35,086,188	)		$ (43,769,230	)		$ (55,519,896	)		$ (89,839,534	)